`
`Filed on behalf of:
`Mylan Pharmaceuticals Inc.
`Joseph M. Reisman
`Jay R. Deshmukh
`
`KNOBBE, MARTENS, OLSON & BEAR, LLP
`2040 Main Street, 14th Floor
`Irvine, CA 92614
`Fax: (949) 760-9502
`Ph.: (949) 760-0404
`E-mail: BoxMylan2@knobbe.com
`
`By:
`
`
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________________________
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner
`
`v.
`
`NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,
`Patent Owners
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case No. 2015-00268
`Patent 6,335,031
`
`
`
`
`
`
`
`
`
`
`
`
`CORRECTED EXHIBIT LIST
`
`
`
`
`
`Mylan v. Novartis
`IPR2015-00268
`
`
`CORRECTED EXHIBIT LIST
`
`Exhibit No.
`
`Description
`
`Ex. 1001
`
`U.S. Patent No. 6,335,031, issued January 1, 2002
`
`Ex. 1002
`
`Ex. 1003
`
`Ex. 1004
`
`Ex. 1005
`
`Ex. 1006
`
`Ex. 1007
`
`UK Patent Application GB 2,203,040 A, to Enz, published
`October 12, 1988 (“Enz”)
`
`Handbook of Pharmaceutical Excipients, A. Wade and P. J.
`Weller (eds.) 1994, 2nd Edition, The Pharmaceutical Press
`London (the “Handbook”)
`
`Japanese Patent Application Publication No. JP 59-184121
`to Sasaki et al., published October 19, 1984
`
`Certified English Translation of Japanese Patent
`Application Publication No. JP 59-184121 to Sasaki et al.
`(“Sasaki”)
`
`PCT Publication No. WO 95/024172 to Ebert et al,
`published September 14, 1995 (“Ebert”)
`
`Carey & Sundberg, Advanced Organic Chemistry, Part A:
`Structure and Mechanism, 3rd Edition (Plenum Press, NY), pp.
`651-727 (1990).
`
`Ex. 1008
`
`U.S. Patent 4,948,807 (“Rosin”)
`
`Ex. 1009
`
`Elmalem et al. 1991, Neuropharmacology 30: 1059-1064
`(“Elmalem”)
`
`Ex. 1010
`
`Declaration of Agis Kydonieus, Ph.D.
`
`Ex. 1011
`
`Declaration of Christian Schöneich, Ph.D.
`
`Ex. 1012
`
`“Safety/Tolerability Trial of SDZ ENA 713 in Patients with
`Probable Alzheimer’s Disease,” John J. Sramek et al., Life
`Sciences, Vol. 58, No. 15, pp. 1201-1207 (1996) (“Sramek”)
`
`1
`
`
`
`Mylan v. Novartis
`IPR2015-00268
`
`
`Exhibit No.
`
`Description
`
`Ex. 1013
`
`Ex. 1014
`
`Ex. 1015
`
`Ex. 1016
`
`Ex. 1017
`
`Ex. 1018
`
`Ex. 1019
`
`Ex. 1020
`
`Ex. 1021
`
`Ex. 1022
`
`“New acetylcholinesterase inhibitor shows promise in largest
`Alzheimer’s trial to date,” Formulary, Vol. 32, Dec. 1997
`(“Formulary Article”)
`
`ICH Topic Q 1 A, Stability Testing Guidelines: Stability Testing
`of New Drug Substances and Products (CPMP/ICH/380/95)
`
`Connors, Amidon, & Stella, Oxidation and Photolysis in Chemical
`Stability of Pharmaceuticals – A Handbook for Pharmacists (2nd
`Edition), John Wiley & Sons, NY (1986), pp. 82-114
`
`Howard C. Ansel, Introduction to Pharmaceutical Dosage Forms,
`4th Edition, Lea & Febiger, Philadelphia (1985), pp. 83-116
`
`Ho-Leung Fung, Chapter 7 – Chemical Kinetics and Drug Stability
`in MODERN PHARMACEUTICS (G.S. Banker and C.T. Rhodes,
`eds.), Marcel Dekker, NY (1979), pp. 227-62.
`Miguel-Hidalgo, J., 2000, Current Opinion in CPNS Investigations
`Drugs, 2000 2(4):438-453
`
`Boccardi G. et al. Photochemical Iron(III)-Mediated Autoxidation
`of Dextromethorphan. Chemical & Pharmaceutical Bulletin. Vol.
`37, 308–310 (1989)
`
`Bateman, L., Olefin Oxidation, Quarterly Review (1954) Vol. 8,
`pp. 147–167
`
`Linnell, R.H., The Oxidation of Nicotine. I. Kinetics of the Liquid
`Phase Reaction Near Room Temperature. Tobacco Science, Vol.
`4, pp. 89-91 (1960).
`Resume/Curriculum Vitae of Agis Kydonieus, Ph.D.
`
`Ex. 1023
`
`Resume/Curriculum Vitae of Christian Schöneich, Ph.D.
`
`2
`
`
`
`Mylan v. Novartis
`IPR2015—00268
`
`
`
`
`EX. 1024
`
`
`
`
`
`US. Patent No. 5,602,176, issued Feb. 11, 1997
`
`Respectfully submitted,
`
`KNOBBE, MARTENS, OLSON & BEAR, LLP
`
`Dated:
`
`IKE/g 70470{
`
`By:
`
`flflg
`
`
`
`oseph M. Reisman
`Reg. No. 43,878
`Customer No. 20,995
`
`Attorneys for Petitioner
`MYLAN PHARMACEUTICALS INC.
`
`(949) 760-0404
`
`
`
`Mylan V. Novartis
`IPR2015—00268
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that true and correct copies of the foregoing CORRECTED
`
`EXHIBIT LIST AND CORRECTED EXHIBITS 1007, 1010, 1011, 1019, AND
`
`1020 are being served on February 20, 2015, Via email pursuant to 37 CPR. §
`
`42.6(e) per agreement of the parties,
`
`to counsel for Novartis AG and LTS
`
`Lohmann Therapie-Systeme AG at the address below:
`
`ExelonPatchIPR@fchs.com
`
`Raymond R. Mandra
`Fitzpatrick, Cella, Harper & Scinto
`1290 Avenue of the Americas
`
`New York, NY 10104
`
`Dated:
`
`(£3. 2‘9" Z‘ME
`
`19832523
`
`By:
` seph M. Reisman
`
`Attorney for Petitioner
`M Y 1 ,AN PHARMACEUTICALS INC.
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
